Company intelligence / Profile preview
HanchorBio Inc.
Taipei, Taiwanhanchorbio.com ↗
- Ownership
- Private
- Development stage
- Clinical
01
Overview
Lead product HCB101 is in Phase 1/2 clinical trials. It's an engineered SIRPα protein fused to the Fc region of IgG4 that triggers phagocytosis activity of macrophages by blocking the "do not eat me" SIRPα-CD47 signaling pathway. Pre-clinical data suggests it's potentially safer and more potent than anti-CD47 monoclonal antibodies currently in clinical trials[5].
- Therapeutic areas
- Oncology
- Modalities
- BiologicsFusion proteinsDesigner biologicsImmune cell therapy
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Henlius (Shanghai Henlius Biotech Inc.)[3]
Beyond the preview
Go deeper on HanchorBio Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HanchorBio Inc..